Abstract
Purpose of Review
Cytolytic vaginosis is a controversial condition that some clinicians have traditionally included as a potential cause of vulvovaginal symptoms despite the lack of scientific evidence.
Recent Findings
Recent articles have focused on the evaluation of patients once they carry the diagnosis of cytolytic vaginosis, rather than on diagnostic criteria.
Summary
Our review revealed inadequate criteria for excluding other causes of vulvovaginal symptoms, especially VVC, when diagnosing women with cytolytic vaginosis. Treatment recommendations have remained stagnant with no single case report or case series with detailed information about affected patients. Finally, with the inconsistencies in sampling sites and inadequacies in sampling techniques across studies, the reported evidence of lactobacilli overgrowth is unreliable and cannot be used to support the diagnosis of cytolytic vaginosis. Any future investigations of the condition would need to have strict criteria for diagnosis which can be reproduced by other investigators, so that common ground for diagnosis can begin as a basis for studies. We further recommend that any study evaluating patient treatments include information about patient demographics, details about their treatment, and the results in terms of changes in symptoms and findings.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance
Anderson MR, Klink K, Cohrssen A. Evaluation of vaginal complaints. Jama. 2004;291(11):1368–79.
Vallor AC, Antonio MA, Hawes SE, Hillier SL. Factors associated with acquisition of, or persistent colonization by, vaginal lactobacilli: role of hydrogen peroxide production. J Infect Dis. 2001;184(11):1431–6.
Beigi RH, Wiesenfeld HC, Hillier SL, Straw T, Krohn MA. Factors associated with absence of H2O2-producing Lactobacillus among women with bacterial vaginosis. J Infect Dis. 2005;191(6):924–9.
• Cibley LJ, Cibley LJ. Cytolytic vaginosis. Am J Obstet Gynecol. 1991;165(4 Pt 2):1245–9 This is the original cytolytic vaginosis article.
Batashki I, Markova D, Milchev N. Frequency of cytolytic vaginosis--examination of 1152 patients. Akush Ginekol (Sofiia). 2009;48(5):15–6.
Demirezen S. Cytolytic vaginosis: examination of 2947 vaginal smears. Cent Eur J Public Health. 2003;11(1):23–4.
Shopova E, Tiufekchieva E, Karag'ozov I, Koleva V. Cytolytic vaginosis--clinical and microbiological study. Akush Ginekol (Sofiia). 2006;45(Suppl 2):12–3.
• Yang S, Zhang Y, Liu Y, Wang J, Chen S, Li S. Clinical significance and characteristic clinical differences of cytolytic vaginosis in recurrent vulvovaginitis. Gynecol Obstet Investig. 2017;82(2):137–43 This study includes yeast culture in the diagnostic criteria for CV in patients with recurrent vulvovaginitis.
Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(RR-03):1–137.
• Committee on Practice Bulletins—Gynecology. Vaginitis in nonpregnant patients: ACOG Practice Bulletin, Number 215. Obstet Gynecol. 2020;135(1):e1–e17 The ACOG Practice Bulletin on principles of vaginitis does not include cytolytic vaginosis as a potential cause of vaginitis.
Sobel JD. Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 1985;152(7 Pt 2):924–35.
Beghini J, Linhares IM, Giraldo PC, Ledger WJ, Witkin SS. Differential expression of lactic acid isomers, extracellular matrix metalloproteinase inducer, and matrix metalloproteinase-8 in vaginal fluid from women with vaginal disorders. BJOG. 2015;122(12):1580–5.
Cerikcioglu N, Beksac MS. Cytolytic vaginosis: misdiagnosed as candidal vaginitis. Infect Dis Obstet Gynecol. 2004;12(1):13–6.
Sanches JM, Giraldo PC, Amaral R, Eberlin MN, Marques LA, Migliorini I, et al. Vaginal lipidomics of women with vulvovaginal candidiasis and cytolytic vaginosis: a non-targeted LC-MS pilot study. PLoS One. 2018;13(8):e0202401.
Hu Z, Zhou W, Mu L, Kuang L, Su M, Jiang Y. Identification of cytolytic vaginosis versus vulvovaginal candidiasis. J Low Genit Tract Dis. 2015;19(2):152–5.
Xu H, Zhang X, Yao W, Sun Y, Zhang Y. Characterization of the vaginal microbiome during cytolytic vaginosis using high-throughput sequencing. J Clin Lab Anal. 2019;33(1):e22653.
Churchman SA, Moss JA, Baum MM. Accurate measurement of female genital tract fluid dilution in cervicovaginal lavage samples. J Chromatogr B Anal Technol Biomed Life Sci. 2016;1017–1018:75–81.
Dezzutti CS, Hendrix CW, Marrazzo JM, Pan Z, Wang L, Louissaint N, et al. Performance of swabs, lavage, and diluents to quantify biomarkers of female genital tract soluble mucosal mediators. PLoS One. 2011;6(8):e23136.
Mitchell C, Paul K, Agnew K, Gaussman R, Coombs RW, Hitti J. Estimating volume of cervicovaginal secretions in cervicovaginal lavage fluid collected for measurement of genital HIV-1 RNA levels in women. J Clin Microbiol. 2011;49(2):735–6.
Azevedo S, Lima-Silva J, Vieira-Baptista P. Impact of the sampling site in the result of wet mount microscopy. J Low Genit Tract Dis. 2019;23(2):176–81.
Bercovici B, Schechter A, Golan J. Cytolysis in normal and complicated pregnancy. Am J Obstet Gynecol. 1973;116(6):831–4.
Lustig G, Ryan CM, Secor WE, Johnson PJ. Trichomonas vaginalis contact-dependent cytolysis of epithelial cells. Infect Immun. 2013;81(5):1411–9.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Malia Voytik has no conflicts of interest to disclose. Paul Nyirjesy has received research funds from the Curatek Pharmaceuticals, Mycovia Pharmaceuticals, and Scynexis, Inc. and has served as a consultant for the Mycovia Pharmaceuticals, Hologic Corporation, Lupin Pharmaceuticals, Hologic, Inc., Scynexis, Inc., Daré Bioscience, Inc., and Becton, Dickinson.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Female Genital Tract Infections
Rights and permissions
About this article
Cite this article
Voytik, M., Nyirjesy, P. Cytolytic Vaginosis: a Critical Appraisal of a Controversial Condition. Curr Infect Dis Rep 22, 26 (2020). https://doi.org/10.1007/s11908-020-00735-w
Published:
DOI: https://doi.org/10.1007/s11908-020-00735-w